AbstractThe National Institute of Clinical Excellence (NICE) was established in the United Kingdom in April 1999 to issue guidance for the National Health Service (NHS) on the use of selective new health care interventions. This article describes the NICE requirements for both incidence-based cost-effectiveness analyses and prevalence-based estimates of the aggregate NHS impact of the new drug. The article demonstrates how both of these requirements can be met using Markov modeling techniques. A Markov model for a hypothetical new treatment for HIV infection is used as an illustration of how to generate the estimates that are required by NICE. The article concludes with a discussion of the difficulties of obtaining data of sufficient qualit...
Background: National Institute for Health and Care Excellence (NICE) clinical guidelines (CGs) make ...
Contains fulltext : 51022.pdf (publisher's version ) (Closed access)OBJECTIVE: Mar...
Objectives Before an intervention is publicly funded within the United Kingdom, the cost-effectiv...
AbstractThe National Institute of Clinical Excellence (NICE) was established in the United Kingdom i...
The primary objectives of this research were to (1) estimate survival functions and the natural hist...
Objective: Markov models are the standard method used in cost-effectiveness studies to represent the...
The National Institute for Clinical Excellence (NICE) responds to requests by the Department of Heal...
ArticleThe aim of this study is to model the progression of HIV/AIDS disease and evaluate the cost o...
Decision-making processes in medicine rely increasingly on modelling and simulation techniques; they...
Paolo Sacchi1, Savino FA Patruno1, Raffaele Bruno1, Serena Maria Benedetta Cima1, Pietro Previtali2,...
The total health care cost for human immunodeficiency virus (HIV) patients has constantly grown in r...
Providing private antiretroviral therapy (ART) care for public sector patients could increase access...
BACKGROUND AND AIMS: The total health care cost for human immunodeificiency virus (HIV) patients ha...
Recommendations made by the UK's National Institute for Health and Care Excellence (NICE) consider a...
In the recent past, both non-parametric and parametric approaches have consistently been used to mod...
Background: National Institute for Health and Care Excellence (NICE) clinical guidelines (CGs) make ...
Contains fulltext : 51022.pdf (publisher's version ) (Closed access)OBJECTIVE: Mar...
Objectives Before an intervention is publicly funded within the United Kingdom, the cost-effectiv...
AbstractThe National Institute of Clinical Excellence (NICE) was established in the United Kingdom i...
The primary objectives of this research were to (1) estimate survival functions and the natural hist...
Objective: Markov models are the standard method used in cost-effectiveness studies to represent the...
The National Institute for Clinical Excellence (NICE) responds to requests by the Department of Heal...
ArticleThe aim of this study is to model the progression of HIV/AIDS disease and evaluate the cost o...
Decision-making processes in medicine rely increasingly on modelling and simulation techniques; they...
Paolo Sacchi1, Savino FA Patruno1, Raffaele Bruno1, Serena Maria Benedetta Cima1, Pietro Previtali2,...
The total health care cost for human immunodeficiency virus (HIV) patients has constantly grown in r...
Providing private antiretroviral therapy (ART) care for public sector patients could increase access...
BACKGROUND AND AIMS: The total health care cost for human immunodeificiency virus (HIV) patients ha...
Recommendations made by the UK's National Institute for Health and Care Excellence (NICE) consider a...
In the recent past, both non-parametric and parametric approaches have consistently been used to mod...
Background: National Institute for Health and Care Excellence (NICE) clinical guidelines (CGs) make ...
Contains fulltext : 51022.pdf (publisher's version ) (Closed access)OBJECTIVE: Mar...
Objectives Before an intervention is publicly funded within the United Kingdom, the cost-effectiv...